Sotera Health (SHC) Stock Forecast & Price Target

Sotera Health is positioned for significant financial growth, with projected adjusted EBITDA expanding at a compound annual rate of 6.7% from $589 million in 2025 to $716 million by 2028, indicating an increase in adjusted EBITDA margin from 50.8% to 51.7%. The company anticipates adjusted gross profit to grow at a 6.4% compound annual rate from $657 million in 2025 to $791 million in 2028, accompanied by a steady increase in adjusted gross margin. Additionally, the positive momentum in revenue growth, estimated at 4.5-6% on a constant currency basis, along with an encouraging shift towards higher-margin services within the Nelson Labs segment, supports a favorable outlook for Sotera Health's market performance.

Sotera Health's adjusted EBITDA margin has experienced a decline of approximately 180 basis points from 2021 to 2024, primarily influenced by inflation and overstaffing issues within its Nelson Labs business, which has seen margins drop significantly. Furthermore, the company's recent performance in its advisory services is described as one of the worst in its history, exacerbated by a lack of FDA activity and resulting in a projected mid-single-digit sales decline for Nelson Labs in 2025. Finally, despite historical organic revenue growth, current pressures stemming from customer supply chain challenges and the loss of higher-margin services have negatively impacted the company’s top line and overall financial outlook.